FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma

被引：14

作者：

Nakaigawa, Noboru ^{[1
]}

Kondo, Keiichi ^{[1
]}

Kaneta, Tomohiro ^{[2
]}

Tateishi, Ukihide ^{[2
]}

Minamimoto, Ryogo ^{[2
]}

Namura, Kazuhiro ^{[1
]}

Ueno, Daiki ^{[1
]}

Kobayashi, Kazuki ^{[3
]}

Kishida, Takeshi ^{[4
]}

Ikeda, Ichiro ^{[5
]}

Hasumi, Hisashi ^{[1
]}

Makiyama, Kazuhide ^{[1
]}

Hayashi, Narihiko ^{[1
]}

Osaka, Kimito ^{[1
]}

Muraoka, Kentaro ^{[1
]}

Izumi, Koji ^{[1
]}

Kawahara, Takashi ^{[1
]}

Teranishi, Jun-ichi ^{[1
]}

Miyoshi, Yasuhide ^{[1
]}

Yumura, Yasushi ^{[1
]}

Uemura, Hiroji ^{[1
]}

Inoue, Tomio ^{[2
]}

Yao, Masahiro ^{[1
]}

机构：

[1] Yokohama City Univ, Grad Sch Med, Dept Urol, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan

[2] Yokohama City Univ, Grad Sch Med, Dept Radiol, Yokohama, Kanagawa, Japan

[3] Yokosuka Kyosai Hosp, Dept Urol, Yokosuka, Kanagawa, Japan

[4] Kanagawa Canc Ctr, Dept Urol, Yokohama, Kanagawa, Japan

[5] Yokohama Minami Kyosai Hosp, Dept Urol, Yokohama, Kanagawa, Japan

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2018年 / 81卷 / 04期

关键词：

Renal cell carcinoma; FDG PET/CT; Prognosis; Molecular targeted therapy; POSITRON-EMISSION-TOMOGRAPHY; INTERFERON-ALPHA; DISTANT METASTASES; EVEROLIMUS; SUNITINIB; SURVEILLANCE; SORAFENIB; BIOMARKER;

D O I：

10.1007/s00280-018-3542-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We investigated prospectively whether F-18-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG PET/CT) can predict the overall survival (OS) of patients with advanced renal cell carcinoma (RCC) previously treated by molecular targeted therapies. Between 2009 and 2016, 81 patients who had received single molecular targeted therapies (43 sorafenib, 27 sunitinib, 8 temsirolimus and others) and were scheduled for second line molecular targeted therapies for advanced RCC were enrolled in this prospective study. FDG PET/CT was performed after first line molecular targeted therapies, the max SUVmax (highest standardized uptake value for each patient) recorded, and its association with OS compared with those of known risk factors. The median follow-up was 15.4 months (range 0.9-97.4 months). The max SUVmax of the 81 subjects ranged from undetectable to 23.0 (median 7.1). Patients with high max SUVmax had a poor prognosis and multivariate analysis with established risk factors showed that it was an independent predictor of survival (p < 0.001; hazard ratio 1.156; 95% confidence interval 1.080-1.239). Subclassification of patients by max SUVmax showed that the median OS of patients with max SUVmax < 7.0 (39), 7.0-12.0 (30), and ae 12.0 (12) were 32.8, 15.2, and 6.0 months, respectively. These differences are statistically significant (< 7.0 versus 7.0-12.0: p = 0.0333, 7.0-12.0 versus ae 12.0: p = 0.0235). The max SUVmax by FDG PET/CT of patients with RCC evaluated after their first molecular targeted therapy predicts OS. FDG PET/CT is a useful "imaging biomarker" for patients with advanced RCC planning sequential molecular targeted therapies.

引用

页码：739 / 744

页数：6

共 30 条

[21]

Motzer Robert J, 2015, J Natl Compr Canc Netw, V13, P151

[22] Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma [J].

Motzer, Robert J. ;

Hutson, Thomas E. ;

Cella, David ;

Reeves, James ;

Hawkins, Robert ;

Guo, Jun ;

Nathan, Paul ;

Staehler, Michael ;

de Souza, Paul ;

Merchan, Jaime R. ;

Boleti, Ekaterini ;

Fife, Kate ;

Jin, Jie ;

Jones, Robert ;

Uemura, Hirotsugu ;

De Giorgi, Ugo ;

Harmenberg, Ulrika ;

Wang, Jinwan ;

Sternberg, Cora N. ;

Deen, Keith ;

McCann, Lauren ;

Hackshaw, Michelle D. ;

Crescenzo, Rocco ;

Pandite, Lini N. ;

Choueiri, Toni K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (08) :722-731

[23] The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy [J].

Nakaigawa, Noboru ;

Kondo, Keiichi ;

Ueno, Daiki ;

Namura, Kazuhiro ;

Makiyama, Kazuhide ;

Kobayashi, Kazuki ;

Shioi, Koichi ;

Ikeda, Ichiro ;

Kishida, Takeshi ;

Kaneta, Tomohiro ;

Minamimoto, Ryogo ;

Tateishi, Ukihide ;

Inoue, Tomio ;

Yao, Masahiro .

BMC CANCER, 2017, 17

[24] FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma [J].

Nakaigawa, Noboru ;

Kondo, Keiichi ;

Tateishi, Ukihide ;

Minamimoto, Ryogo ;

Kaneta, Tomohiro ;

Namura, Kazuhiro ;

Ueno, Daiki ;

Kobayashi, Kazuki ;

Kishida, Takeshi ;

Ikeda, Ichiro ;

Hasumi, Hisashi ;

Makiyama, Kazuhide ;

Kubota, Yoshinobu ;

Inoue, Tomio ;

Yao, Masahiro .

BMC CANCER, 2016, 16 :67

[25] Impact of maximum Standardized Uptake Value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report [J].

Namura, Kazuhiro ;

Minamimoto, Ryogo ;

Yao, Masahiro ;

Makiyama, Kazuhide ;

Murakami, Takayuki ;

Sano, Futoshi ;

Hayashi, Narihiko ;

Tateishi, Ukihide ;

Ishigaki, Hanako ;

Kishida, Takeshi ;

Miura, Takeshi ;

Kobayashi, Kazuki ;

Noguchi, Sumio ;

Inoue, Tomio ;

Kubota, Yoshinobu ;

Nakaigawa, Noboru .

BMC CANCER, 2010, 10

[26] Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma [J].

Park, Jong Wook ;

Jo, Moon Ki ;

Lee, Hyun Moo .

BJU INTERNATIONAL, 2009, 103 (05) :615-619

[27] Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial [J].

Rini, Brian I. ;

Escudier, Bernard ;

Tomczak, Piotr ;

Kaprin, Andrey ;

Szczylik, Cezary ;

Hutson, Thomas E. ;

Michaelson, M. Dror ;

Gorbunova, Vera A. ;

Gore, Martin E. ;

Rusakov, Igor G. ;

Negrier, Sylvie ;

Ou, Yen-Chuan ;

Castellano, Daniel ;

Lim, Ho Yeong ;

Uemura, Hirotsugu ;

Tarazi, Jamal ;

Cella, David ;

Chen, Connie ;

Rosbrook, Brad ;

Kim, Sinil ;

Motzer, Robert J. .

LANCET, 2011, 378 (9807) :1931-1939

[28] Renal cell carcinoma [J].

Rini, Brian I. ;

Campbell, Steven C. ;

Escudier, Bernard .

LANCET, 2009, 373 (9669) :1119-1132

[29] Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course [J].

Ueno, Daiki ;

Yao, Masahiro ;

Tateishi, Ukihide ;

Minamimoto, Ryogo ;

Makiyama, Kazuhide ;

Hayashi, Narihiko ;

Sano, Futoshi ;

Murakami, Takayuki ;

Kishida, Takeshi ;

Miura, Takeshi ;

Kobayashi, Kazuki ;

Noguchi, Sumio ;

Ikeda, Ichiro ;

Ohgo, Yoshiharu ;

Inoue, Tomio ;

Kubota, Yoshinobu ;

Nakaigawa, Noboru .

BMC CANCER, 2012, 12

[30] 18F-FDG PET/CT Imaging for an Early Assessment of Response to Sunitinib in Metastatic Renal Carcinoma: Preliminary Study [J].

Vercellino, Laetitia ;

Bousquet, Guilhem ;

Baillet, Georges ;

Barre, Emmanuelle ;

Mathieu, Olivier ;

Just, Pierre-Alexandre ;

Desgrandchamps, Francois ;

Misset, Jean-Louis ;

Hindie, Elif ;

Moretti, Jean-Luc .

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2009, 24 (01) :137-144

← 1 2 3 →